Bedfont named International Business for the 2nd year in a row at the South East Federation of Small Businesses Awards
On Friday 12th April, Bedfont Scientific ltd was recognised as
International Business of the Year for its 2nd year in a row at the
South East Federation of Small Businesses (FSB) Awards 2019.
The FSB hosts annual Celebrating Small Business Awards to recognise
the best small businesses across the UK. The UK is split into 12
regions and each region holds its own ceremony, with all regional
winners going through to compete in the Nationals taking place on 23rd
May at Evolution Battersea.
Despite being a small family business with only 43 employees,
Bedfont’s medical devices can be found worldwide, with export sales
accounting for 80% of turnover.
Jason Smith, Managing Director at Bedfont, says,
“We are so proud and thrilled to have been named International Business
of the Year 2019. There are a lot of great companies out there and we
didn’t expect to be recognised for 2 years in a row. This award wouldn’t
be possible without the hard work and dedication of the Bedfont family
and its distributors, its thanks to them we can continue to innovate
healthcare worldwide.”
This accolade is Bedfont’s 3rd regional exporting recognition and its 7th exporting award so far.
Bedfont® has announced the US Food and Drug Administration (FDA) clearance for its carbon monoxide (CO) breath analysis monitor which determines levels of CO poisoning
The ToxCO is a breath analysis monitor that measures exhaled carbon
monoxide (CO) to give healthcare personnel an idea of CO levels in the
blood, allowing them to triage cases of CO poisoning.
Unlike traditional methods, breath analysis with the ToxCO is
non-invasive with instant results, saving time in critical situations.
Breath samples can be taken via a low-cost mouthpiece allowing for
point-of-care CO checking for mass casualties, aiding the decision of
whether or not a patient needs to be treated at hospital. For patients
who are unconscious or injured, a face mask option offers a modified
sampling technique to indicate for CO poisoning. The monitor also
automatically samples ambient air from switch-on, acting as an alarm
when CO levels in the environment reach harmful levels.
Jason Smith, Managing Director at Bedfont comments, “Not
only can our breath analysis monitor help to evaluate patients quickly
and effectively for CO poisoning, but it can also reduce emergency
department visits and hospitalizations. We are thrilled with the FDA
approval of the ToxCO; we believe it will be game-changer for healthcare
personnel in America.”
Bedfont already has an exclusive USA distributor for the ToxCO monitor, CoVita. Its President, Jason Aversano, expressed his excitement about the 510(K), stating
“the ToxCO will be a useful tool for healthcare professionals such as
paramedics in Firefighter Rehab. We believe it will fundamentally change
how people are assessed for CO poisoning in the United States.”
Bedfont® Scientific Ltd. scoops Exporter of the Year for the 3rd time in a row at the Kent Invicta Chamber of Commerce awards.
On Thursday 21st March, the Kent Invicta Chamber of Commerce held
their annual business awards and 2nd generation family business,
Bedfont®, was named Exporter of the Year for the 3rd year in a row.
The awards, now in its 13th year, celebrates the excellent abundance of businesses in the county of Kent.
Bedfont®, based in Harrietsham, specialises in the design and
manufacture of breath analysis medical devices. Its range of carbon
monoxide (CO) monitors include the Smokerlyzer®, used for smoking
cessation, and the ToxCO®, used by emergency services, to screen for CO
poisoning. The NObreath® FeNO monitor provides accurate analysis of
airway inflammation to aid in the diagnosis and management of asthma,
and the Gastrolyzer® range aids in the detection of gastrointestinal
disorders and food intolerances.
Despite being a small family business with only 43 employees,
Bedfont®’s medical analysers can be found worldwide, with export sales
accounting for 80% of turnover, thanks to continuous innovation from the
Bedfont® family and its network of carefully selected distributors,
Bedfont®’s extended family.
Jason Smith, Managing Director at Bedfont®, comments, “Exporting
for any company is no easy feat. For Bedfont®, our greatest challenge
can be our size, but with dedicated employees and distributors we have
managed to achieve this. We are utterly humbled to have won this award
for the 3rd year in a row – it really acknowledges the efforts of the
Bedfont® family, our employees and distributors, and I am honoured to
share this prestigious award with them.”
Kent medical device manufacturer receives a manufacturing accolade in the GHP Biotechnology Awards
Bedfont, who has specialised in the design and manufacture of breath
and gas analysis monitors since 1976, has been named Best Breath &
Gas Monitoring Instruments Manufacturer 2019 in the Global Health &
Pharma (GHP) Biotechnology Awards.
The awards, now in their 3rd year, aim to highlight those
responsible for the “life-changing innovations and developments” in the
healthcare and pharmaceutical industries.
Jason Smith, Managing Director at Bedfont, comments,
“We take great pride in being an innovative company whose products are
used to save lives. We’ve been manufacturing breath analysis medical
devices for over 40 years, but it is still quite a niche concept in some
areas of the world. This award is a testament to our high-quality
products and we hope that it will help us to reach new medical markets,
enabling us to keep innovating and improving health, one breath at a
time.”
Kent medical device manufacturer, Bedfont Scientific Ltd., signs a multiyear ODM deal to supply MGC Diagnostics Corporation with its new NObreath®
MGC Diagnostics Corporation (MGCD), through its Medical Graphics and
Medisoft subsidiaries, is a global medical technology company dedicated
to the delivery of diagnostic solutions for detecting, classifying, and
managing cardiorespiratory disease. MGCD has signed an Original Design
Manufacturer (ODM) agreement with Bedfont for the new NObreath®
Fractional exhaled Nitric Oxide (FeNO) monitor.
FeNO is a biomarker for airway inflammation, helping in the control
and diagnosis of asthma and also the differentiation between asthma and
other respiratory diseases. Measuring FeNO through breath analysis,
making the process quick, simple and non-invasive for both the GP and
the patient. Interpreting FeNO levels aids in identifying patients who
do/do not require on-going treatment1 whilst also differentiating
between allergic (eosinophilic) and non-allergic asthma2, and if used
daily, FeNO measurements can help to predict exacerbations and attacks.3
The ODM agreement for NObreath® means Bedfont designs and
manufactures the monitor and MGCD distributes MGCD branded product. The
MGCD product, called FeNObreath, is differentiated from the NObreath® by
direct integration with MGCD diagnostics devices.
Matt Margolies, President and Chief Operating Office at MGC Diagnostics commented, “Bedfont’s
NObreath® is an ideal device to expand our existing range of
high-quality diagnostic solutions. We will sell the FeNObreath both as a
stand-alone device and as an integrated module to our diagnostic
products. Medical Graphics and Medisoft’s selling teams are excited to
add this innovative product to our product portfolios.”
Jason Smith, Managing Director at Bedfont, adds, “The
NObreath® mission is to help improve asthma diagnosis and management
for adults and children worldwide through FeNO monitoring. This new
strategic partnership will enable Bedfont to access new markets
worldwide and further highlight FeNO testing and its benefits globally.”
REFERENCES
1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris
MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor.
Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide
Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169.
pp 473-478, 2004.
Bedfont, based in Maidstone, wins South East Exporter of the Year at the South East Health Technology Alliance Awards
Bedfont Scientific Ltd., who has specialised in the design and
manufacture of breath analysis medical devices for over 40 years, was
named Exporter of the Year at the South East Health Technology Alliance
Awards on 11th February 2019.
This is the 2nd regional award that Bedfont has achieved after
winning their 1st regional award, also for exporting, last year. This
win means Bedfont will be going through to the National Medilink Awards
taking place at the NEC Birmingham in May.
Jason Smith, Managing Director at Bedfont, explains,
“In 10 years we’ve managed to establish a network of distributors, whom
we regard as an extension of the Bedfont Family. Our first distributor
was established in 1988 and we still work with them today. Through this
network, we have managed to increase our exports significantly, and they
now account for 80% of our turnover.”
Dr David Parry, CEO, SEHTA, said, “Once again our
awards have demonstrated the excellence of small health technology
companies in the South East. This year was once again very competitive;
it’s a primary aim of SEHTA to help such companies’ access public and
private sector markets with their innovative products and services”.
Rob Berry, Head of Innovation, Kent Surrey Sussex Academic Health Science Network (KSS AHSN), said,
“KSS AHSN has a key role to help companies navigate the healthcare
maze, so we’re delighted to continue to support the SEHTA Healthcare
Business Awards. The awards help to recognise and reward great
innovative work taking place across the region and we congratulate all
the winners and finalists on their success”.
Bedfont’s long-standing UK distributor, Intermedical UK, will be exhibiting their breath analysis medical products at the annual ARTP conference.
A distributor for nearly 10 years, Intermedical UK will be exhibiting
the 2nd generation NObreath at the annual Association for Respiratory
Technology & Physiology (ARTP) conference and can be found at Stand
25.
FeNO monitoring with the NObreath offers a quick, simple and
non-invasive method of assessing airway inflammation for aiding the
diagnosis and management of asthma. Interpreting FeNO levels aids in
identifying patients who do/do not require on-going treatment(1) whilst
also differentiating between allergic (eosinophilic) and non-allergic
asthma(2), and if used daily, FeNO measurements can help to predict
exacerbations and attacks(3).
New features for the NObreath includes the ability to save patient
profiles on the device, Bluetooth connectivity, and SteriTouch
technology for optimum infection control. The 2nd generation model also
has a fresh and aesthetically pleasing design with a full-colour
touchscreen. Furthermore, the NObreath comes with free patient
management software allowing the equipment to synchronise with a PC,
enabling reports to be generated, data to be backed up, and much more.
Livio Gagliardi, Acting Managing Director at Intermedical, said,
“We’re excited to bring the NObreath to ARTP this year. It’s a great
opportunity to talk about the benefits of measuring FeNO when monitoring
asthma and airway inflammation – especially now it is recommended in
the NICE guidance. We believe that the new NObreath will make FeNO
monitoring quicker and easier for healthcare professionals and patients
alike.”
This year, ARTP is taking place between 31 January and 1st February in Glasgow.
Bedfont Scientific Ltd. is exhibiting its wide range of medical devices at Arab Health 2019, including its new and improved NObreath® FeNO monitor
Breath analysis medical device manufacturer, Bedfont, will be
returning to Arab Health 2019 – the largest healthcare exhibition in the
Gulf Cooperation Council. They will be exhibiting their wide range of
breath analysis medical devices, including the new and improved NObreath
FeNO monitor.
The NObreath offers a quick, simple and non-invasive method of
measuring FeNO to assess airway inflammation, aiding in the diagnosis
and management of asthma. Interpreting FeNO levels aids in identifying
patients who do/do not require on-going treatment(1) whilst also
differentiating between allergic (eosinophilic) and non-allergic
asthma(2), and if used daily, FeNO measurements can help to predict
exacerbations and attacks(3).
Alongside a fresh and aesthetically pleasing design with a full
colour touchscreen, new features of the 2nd generation NObreath also
include the ability to save patient profiles on the device, Bluetooth
connectivity, and SteriTouch technology for optimum infection control.
Furthermore, the NObreath comes with free patient management software
allowing the equipment to synchronise with a PC, enabling reports to be
generated, data to be backed up, and much more.
Established in 1976, their other monitors include the Smokerlyzer,
used for smoking cessation, and the ToxCO, used by emergency services,
to screen for CO poisoning. The Gastrolyzer range aids in the detection
of gastrointestinal disorders and food intolerances.
Matthew Skinner, Sales Team Manager, said, “Bedfont aims to
continue improving and innovating health, and being the largest
healthcare gathering in the GCC, Arab Health is the perfect place to
find like-minded companies to work with and help raise awareness of the
benefits of breath testing.”
This year, Arab Health is taking place between 28-31 January in Dubai and Bedfont can be found at stand C57, Hall 7.
REFERENCES
1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris
MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor.
Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide
Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169.
pp 473-478, 2004.
2. Coumou HBel E. Improving the diagnosis of eosinophilic
asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March
2017]. Available from:
http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
3. Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation
[Internet]. Taylor & Francis. 2017 [cited 21 September 2017].
Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990
Medical device manufacturer, Bedfont Scientific Ltd., appoints Dr Jafari to the advisory board for its gastrointestinal breath monitoring products
Bedfont, who has specialised in the design and manufacture of breath
analysis medical devices for over 40 years, announces today that Dr
Jafar Jafari will be the first appointment to its Gastrolyzer Medical
Advisory Board.
Head of Upper GI Physiology at the Guy’s and St Thomas’ Foundation
Trust Hospitals, Dr Jafari has an MD in Medicine, a PhD in
Neurogastroenterology, and has been involved in over 100 research
publications regarding gastroenterology. Notably, one of Dr Jafari’s
main areas of interest is Hydrogen and C13 GI breath testing.
The Gastrolyzer range works by measuring exhaled levels of hydrogen
and methane that are produced when the gut breaks down food;
interpreting these gas levels can help to determine gastrointestinal
disorders such as lactose intolerance, IBS (Irritable Bowel Syndrome)
and more.
Jason Smith, Managing Director, says, “We are privileged to welcome
Dr Jafari into our Bedfont Family and onto our Gastrolyzer Medical
Advisory Board. We are very fortunate to be able to call upon his
extensive knowledge and expertise in the gastrointestinal field.”
Dr Jafar Jafari, adds, “The Gastrolyzer range provides an instant,
non-invasive and easy-to-use method for healthcare professionals and
patients to use when investigating gut function. I am privileged to have
been given this opportunity to contribute to Bedfont’s GI breath
testing campaign.”
Bedfont gets into the giving spirit this Christmas with their reverse advent calendar
Christmas is the time for giving, and that’s exactly what the
Kent-based company decided to do this year with their reverse advent
calendar. A popular idea this year, the reverse advent calendar requires
you to put in a gift instead of receiving one and the 2nd generation
family business donated their reverse advent calendar to the homeless
with the help of their Charity of the Year, Porchlight.
Last year, Porchlight found 834 people sleeping rough in Kent – 5
years ago that number was 148, indicating an alarming 463% increase.
Kate Boulding, Corporate Partnerships Manager at Porchlight, comments, “We
are so grateful for the support from Bedfont Scientific Ltd. this year.
As well as collecting useful items for their reverse advent calendars
and making sure our service users feel valued this Christmas, they have
also put loads of effort into their fundraising, which will go towards
vital services and help Porchlight bring more homeless and vulnerable
people in from the cold. It can be a difficult time of year for the
people we support, so with the help of local companies like Bedfont, we
can make Christmas a little brighter for them.”
Jason Smith, Managing Director, adds, “The
rocketing number of homeless people is a growing concern and through the
reverse advent calendar and fundraising for Porchlight, we hope that as
a local company we can help give back to the community as well as raise
awareness. As our Charity of the Year, we have pledged to raise £3000
for Porchlight; 79% of the rough sleepers Porchlight worked with last
year were helped off the streets and so it’s great to know that in
supporting Porchlight, the Bedfont Family can really help to make a
difference.”
Bedfont gets into the giving spirit this Christmas with their reverse advent calendar
